What does this research mean for the field?

GLP-1 receptor agonist therapy in adolescents with obesity is not associated with short-term psychological harm or increased suicidality, and is associated with a significant decrease in depressive symptoms. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate changes in depressive symptoms and suicidality following the initiation of GLP-1 receptor agonist therapy in adolescents with obesity.

September 14, 2026Journal of Pediatric Endocrinology and Metabolism

GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective review

View Full Paper

Ask AI

Bookmark

Authors

JSJeries SaidMedical College of Wisconsin MLMelodee LieglMedical College of Wisconsin APAmy Y. PanMedical College of Wisconsin

Discussion

Member takes

Implication

Retrospective review finds reduced depressive symptoms and no increased suicidality in adolescents with obesity receiving GLP-1 receptor agonists, supporting short-term psychiatric safety.

Key Points

To evaluate changes in depressive symptoms and suicidality following the initiation of GLP-1 receptor agonist therapy in adolescents with obesity.
Retrospective electronic health record review of adolescents aged 12–21 years with obesity (N=44) treated with liraglutide or semaglutide at a single academic pediatric endocrinology center between June 2022 and December 2024.
Depressive symptoms and suicidality were evaluated at baseline and follow-up using the Patient Health Questionnaire-9 (PHQ-9) and Ask Suicide-Screening Questions (ASQ), analyzing paired data with nonparametric tests.
Among adolescents with paired PHQ-9 data (n=15), median scores decreased significantly from 6 (IQR 2–14) at baseline to 1 (IQR 0–5) at follow-up (p=0.003), independent of changes in BMI.
Among adolescents with paired ASQ data (n=23), no increase in suicidality or new suicidal ideation was observed during the follow-up period.

Cite This Study

Said et al. (2026) studied this question.

synapsesocial.com/papers/6aa7dfc60926e14a848b3ddb https://doi.org/10.1515/jpem-2026-0227

View Full Paper

Ask AI

Bookmark

Implication

Retrospective review finds reduced depressive symptoms and no increased suicidality in adolescents with obesity receiving GLP-1 receptor agonists, supporting short-term psychiatric safety.

GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective review

Discussion

Member takes

Implication

Key Points

Cite This Study

GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective review

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider